771565-01-6

Basic information

• Product Name: C₁₁H₈N₂O₂S
• Synonyms: C₁₁H₈N₂O₂S
• CAS NO: 771565-01-6
• Molecular Weight: 232.263
• Mol File: 771565-01-6.mol

Chemical Properties

• CAS DataBase Reference: C₁₁H₈N₂O₂S(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₁H₈N₂O₂S(771565-01-6)
• EPA Substance Registry System: C₁₁H₈N₂O₂S(771565-01-6)

Safety Data

• Hazardous Substances Data: 771565-01-6(Hazardous Substances Data)

Upstream product

• 5398-77-6 para-methanesulfonylbenzaldehyde 
• 109-77-3 malononitrile 

Relevant articles and documents

Isocyanide-based multicomponent reactions: Catalyst-free stereoselective construction of polycyclic spiroindolines

A novel catalyst-free one-pot tandem reaction for the stereoselective construction of polycyclic spiroindolines was developed. This method offers a straightforward access to structurally diverse polycyclic spiroindoline derivatives in high yields (up to 90%) with excellent levels of diastereoselectivity.

Triazole-Pyridine Dicarbonitrile Targets Phosphodiesterase 4 to Induce Cytotoxicity in Lung Carcinoma Cells

Phosphodiesterase 4 (PDE4) is a key enzyme involved in the hydrolysis of cyclic adenosine monophosphate (cAMP) and widely expressed in several types of cancers. The inhibition of PDE4 results in an increased concentration of intracellular cAMP levels that imparts the anti-inflammatory response in the target cells. In the present report, two series of triazolo-pyridine dicarbonitriles and substituted dihydropyridine dicarbonitriles were synthesized using green protocol (TBAB in refluxed water). We next evaluated the title compounds for their cytotoxicity towards lung cancer (A549) cells and identified 7′-[4-(methylsulfonyl)phenyl]-5′-oxo-1′,5′-dihydrospiro[cyclohexane-1,2′-[1,2,4]triazolo[1,5-a]pyridine]-6′,8′-dicarbonitrile (5h) and 7′-(1-methyl-1H-imidazol-2-yl)-5′-oxo-1′,5′-dihydrospiro[cyclohexane-1,2′-[1,2,4]triazolo[1,5-a]pyridine]-6′,8′-dicarbonitrile (5j) as lead analogs with the IC50 values of 15.2 and 24.1 μm, respectively. Furthermore, all the new compounds were tested for PDE4 inhibitory activity and 5j showed relatively good inhibitory activity towards PDE4 with inhibition of 50.9 % at 10 μm. In silico analysis demonstrated the favorable interaction of the title compounds with the target enzyme. Taken together, the present study introduces a new scaffold for the development of novel PDE4 inhibitors to fight against inflammatory diseases.